secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seaport Therapeutics, Inc. (SPTX)
CIK:        0002042347
Form:       8-K
Filed at:   2026-06-08T11:11:42+00:00
Accession:  0001193125-26-260671
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seaport Q1 net loss $25.4M; cash $212.6M; GlyphAgo Ph1 shows liver safety; GlyphAllo Ph2b on track
--------------------------------------------------------------------------------

- Net loss $25.4M (vs $13.1M YoY); R&D expenses $21.4M, up from $10.5M YoY.
- Cash $212.6M at Q1 end; +$260M from May IPO provides runway into 2029.
- GlyphAgo Phase 1 MAD data show therapeutic exposures at doses avoiding liver enzyme elevations, no liver AEs.
- GlyphAllo Phase 2b BUOY-1 enrollment on track; topline data 1H 2027; driving simulation trial dosed, data 2H 2026.
- Sharon Mates appointed to board; upsized IPO raised $260M gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/0001193125-26-260671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/sptx-20260608.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-260671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer